BACKGROUND AND OBJECTIVES: In the presented study the effect of age and cytogenetics on clinical outcome in acute myeloid leukemia (AML) was evaluated. The 1225 patients with de novo AML were separated according to age as follows: A1: 16 to 49 years (n=442), A2: 50 to 59 years (n=246), A3: 60-69 years (n=333), A4: 70 years and older (n=204). DESIGN AND METHODS: Patients were categorized with respect to cytogenetics into 5 groups: C1: t(15;17) (n=107), C2: CBF-AML/inv(16)/t(8;21) (n=171), C3: 11q23/MLL (n=42), C4: complex aberrant karyotype (n=130), C5: other: normal, other abnormalities, 5q-/-5, 7q-/-7, inv(3)/t(3;3), other 3q abnormalities (n=746). For each age category univariate cox regression analysis was performed using age as a continuous variable and C1 to C5 as dichotomous variables. RESULTS: In cohort A1 all parameters were significantly associated with overall survival (OS). However, in multivariate analysis all cytogenetic parameters were independently correlated with OS, while age was not. In cohort A2 only CBF and complex aberrant karyotype were significantly correlated with OS. In A3 t(15;17), complex karyotype and age, and in A4 only complex karyotype and age were significantly associated with OS in univariate and multivariate analyses. Within all cytogenetic subgroups except AML 11q23/MLL there were significant associations between age and OS. INTERPRETATION AND CONCLUSIONS: (i) Both age and cytogenetics are independent prognostic parameters in AML;(ii) up to the age of 49 years age has no major impact on prognosis while the karyotype has; (iii) in patients 50 years and older the influence of age on outcome increases, and (iv) cytogenetics show an independent effect on survival also in patients over 60 years old.
BACKGROUND AND OBJECTIVES: In the presented study the effect of age and cytogenetics on clinical outcome in acute myeloid leukemia (AML) was evaluated. The 1225 patients with de novo AML were separated according to age as follows: A1: 16 to 49 years (n=442), A2: 50 to 59 years (n=246), A3: 60-69 years (n=333), A4: 70 years and older (n=204). DESIGN AND METHODS: Patients were categorized with respect to cytogenetics into 5 groups: C1: t(15;17) (n=107), C2: CBF-AML/inv(16)/t(8;21) (n=171), C3: 11q23/MLL (n=42), C4: complex aberrant karyotype (n=130), C5: other: normal, other abnormalities, 5q-/-5, 7q-/-7, inv(3)/t(3;3), other 3q abnormalities (n=746). For each age category univariate cox regression analysis was performed using age as a continuous variable and C1 to C5 as dichotomous variables. RESULTS: In cohort A1 all parameters were significantly associated with overall survival (OS). However, in multivariate analysis all cytogenetic parameters were independently correlated with OS, while age was not. In cohort A2 only CBF and complex aberrant karyotype were significantly correlated with OS. In A3 t(15;17), complex karyotype and age, and in A4 only complex karyotype and age were significantly associated with OS in univariate and multivariate analyses. Within all cytogenetic subgroups except AML 11q23/MLL there were significant associations between age and OS. INTERPRETATION AND CONCLUSIONS: (i) Both age and cytogenetics are independent prognostic parameters in AML;(ii) up to the age of 49 years age has no major impact on prognosis while the karyotype has; (iii) in patients 50 years and older the influence of age on outcome increases, and (iv) cytogenetics show an independent effect on survival also in patients over 60 years old.
Authors: Meir Wetzler; Krzysztof Mrózek; Jessica Kohlschmidt; Hervé Dombret; Hartmut Döhner; Sylvain Pilorge; Utz Krug; Andrew J Carroll; Richard A Larson; Guido Marcucci; Wolfgang Hiddemann; Thomas Büchner; Clara D Bloomfield Journal: Haematologica Date: 2013-10-04 Impact factor: 9.941
Authors: Yogen Saunthararajah; Mikkael Sekeres; Anjali Advani; Reda Mahfouz; Lisa Durkin; Tomas Radivoyevitch; Ricki Englehaupt; Joy Juersivich; Kathleen Cooper; Holleh Husseinzadeh; Bartlomiej Przychodzen; Matthew Rump; Sean Hobson; Marc Earl; Ronald Sobecks; Robert Dean; Frederic Reu; Ramon Tiu; Betty Hamilton; Edward Copelan; Alan Lichtin; Eric Hsi; Matt Kalaycio; Jaroslaw Maciejewski Journal: J Clin Invest Date: 2015-01-26 Impact factor: 14.808
Authors: Brian L McClune; Daniel J Weisdorf; Tanya L Pedersen; Gisela Tunes da Silva; Martin S Tallman; Jorge Sierra; John Dipersio; Armand Keating; Robert P Gale; Biju George; Vikas Gupta; Theresa Hahn; Luis Isola; Madan Jagasia; Hillard Lazarus; David Marks; Richard Maziarz; Edmund K Waller; Chris Bredeson; Sergio Giralt Journal: J Clin Oncol Date: 2010-03-08 Impact factor: 44.544
Authors: Andrew M Brunner; Traci M Blonquist; Hossein Sadrzadeh; Ashley M Perry; Eyal C Attar; Philip C Amrein; Karen K Ballen; Yi-Bin Chen; Donna S Neuberg; Amir T Fathi Journal: Leuk Res Date: 2014-04-12 Impact factor: 3.156
Authors: Ramon V Tiu; Lukasz P Gondek; Christine L O'Keefe; Jungwon Huh; Mikkael A Sekeres; Paul Elson; Michael A McDevitt; Xiao Fei Wang; Mark J Levis; Judith E Karp; Anjali S Advani; Jaroslaw P Maciejewski Journal: J Clin Oncol Date: 2009-09-21 Impact factor: 44.544